Author(s)

GuoBiao Liang¹, Wei Bu², Na Tao², Yu Wei², LiLi Wu², YuanWen Liu², Lei Gong^3*

Affiliation(s)

¹Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China.

²Pharmacy Department, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, China.

³Guizhou Engineering Research Center for Translational Medicine, Zunyi Medical University, Zunyi 563000, Guizhou, China.

Corresponding Author

Lei Gong

ABSTRACT

Objective: To explore the influence of patient's gender, age and combination of drugs on FK506 blood concentration after organ transplantation (kidney transplantation), monitor and analyze the whole blood trough concentration of tacrolimus in patients after kidney transplantation, and evaluate the effectiveness and safety of tacrolimus treatment by referring to the effective target concentration range of the guidelines and the influence of patients' combination of drugs. Methods: 138 patients after kidney transplantation were collected, and FK506 blood concentration at different time after kidney transplantation was retrospectively analyzed. Statistical analysis was carried out according to gender, age and other groups, and the blood concentration of tacrolimus, intra individual fluctuations of blood concentration and related drugs were analyzed. Results: One month after operation, the FK506 blood concentration gradually decreased with the prolongation of postoperative time. During the same period, there was no significant difference in FK506 plasma concentration between male and female patients of different sexes (P<0.05). Within 3 months after kidney transplantation, the blood concentration of female patients was slightly higher than that of male patients. Three months after operation, the FK506 blood concentration, dosage and blood concentration in the elderly group were significantly lower than those in the young group and the middle-aged group (P<0.05). The immunosuppressive regimen after transplantation was tacrolimus+mycophenolate mofetil+methylprednisolone. Proton pump inhibitors, calcium antagonists and Bailing capsules were commonly used after transplantation; The target blood concentration of tacrolimus was 5.1~6.1 ng · mL ?; At 12 months after transplantation, 47%, 47% and 8% of the patients had in vivo coefficient of variation of tacrolimus blood concentration<20%, 20.1% - 35% and>35%, respectively. Conclusion: Gender, age, combined medication and other factors have a certain impact on the pharmacokinetics of FK506 in vivo. It is necessary to strengthen the evaluation of treatment plans and pharmaceutical monitoring after transplantation, adopt individualized drug delivery plans and timely adjust them, keep the blood concentration of tacrolimus in a reasonable range and reduce fluctuations, and effectively optimize the anti rejection effect.

KEYWORDS

Renal transplantation; Tacrolimus; Blood drug concentration; Medication analysis

CITE THIS PAPER

GuoBiao Liang, Wei Bu, Na Tao, Yu Wei, LiLi Wu, YuanWen Liu, Lei Gong. Monitoring of organ (kidney transplant) transplant drug (tacrolimus) concentrations and analysis of individualized dosing. Journal of Pharmaceutical and Medical Research. 2024, 6(3): 21-26. DOI: 10.61784/jpmr3011.

REFERENCES

[1] Kramer BK, Klinger M, Vítko S et al. Tacrolimus-based steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation, 2012, 4: 492-498．

[2] Zhang X, Liu ZH, Zheng JM et al. Factors affecting tacrolimus blood concentration in renal transplant patients. Journal of Nephrology and Dialysis Kidney Transplantation, 2005, 14: 333-338.

[3] Balicki I. Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs. Pol J Vet Sci, 2012, 15: 667-676．

[4] Zhang Yi, Wang Zhiyu, Wang Zhaoqing et al. Comparison of blood concentration monitoring methods of tacrolimus. Chinese Journal of Pharmacy, 2003, 38(5): 386-388.

[5] Xiang Heli, Hou Jun, Xue Wujun, et al. Clinical observation of FK506 blood trough concentration after kidney transplantation. Journal of the Fourth Military Medical University, 2003, 24 (1): 67.

[6] Shi L, Gong LX, Yao LW et al. Tacrolimus blood concentration monitoring after renal transplantation. Guangdong Medicine,2005,26: 1272-1273.

[7] Gaber AO, Moore LW, Alloway RR et al. Acute rejection characteris-tics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. Transplantation, 2013, 95: 573-579．

[8] Zhang YY, Zhang XD, Li E et al. Analysis of lung infection and prognostic factors in patients after renal transplantation. Hebei Medicine, 2013, 35: 1013-1015.

[9] Yan Wei, Han Xiuwu, Xing Xiaoyan et al. Clinical analysis of leukopenia caused by morphimecrolate and azathioprine after renal transplantation. Hebei Medicine, 2010,32: 1384-1386.

[10] SCALEA JR, LEVI ST,ALLY W, et al. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol, 2016, 12(3): 333-342.

[11] Guidelines for Immunosuppressive Therapy of Renal Transplantation Recipients in China (2016 Edition) Organ transplantation, 2016, 7(5): 327-331.

[12] ISRANI A K, RIAD S M, LEDUC R et al. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from De KAF Genomics. TransplInt, 2013, 26(10): 982－989.

[13] MAGUIRE M, FRANZ T, HAINS D S. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in akidney transplant recipient. Pediatr Transplant, 2012, 16(6) :217-220.

[14] Zou Sulan, Jiang Yan, Chen Rong Clinical analysis of blood concentration monitoring of tacrolimus in renal transplant patients. Chinese Pharmacy, 2012, 23(42): 477-483.

[15] Qiao Xiaoyun, Chen Chong, Jiang Junyi. Quality control evaluation of tacrolimus blood concentration monitored by enzyme enhanced immunoassay. Pharmacy Services and Research, 2010, 10(1): 40-43.